Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients.


Journal

European journal of clinical pharmacology
ISSN: 1432-1041
Titre abrégé: Eur J Clin Pharmacol
Pays: Germany
ID NLM: 1256165

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 11 11 2019
accepted: 01 04 2020
pubmed: 21 4 2020
medline: 4 3 2021
entrez: 21 4 2020
Statut: ppublish

Résumé

To develop and validate a population pharmacokinetic model of ciprofloxacin intravenously in critically ill patients, and determine target attainment to provide guidance for more effective regimens. Non-linear mixed-effects modelling was used for the model development and covariate analysis. Target attainment of an ƒAUC A total of 204 blood samples were collected from 42 ICU patients treated with ciprofloxacin 400-1200 mg/day, with median values for age of 66 years, APACHE II score of 22, BMI of 26 kg/m The model described the pharmacokinetics of ciprofloxacin in ICU patients adequately. No significant covariates were found and high inter-individual variability of ciprofloxacin pharmacokinetics in ICU patients was observed. The poor target attainment supports the use of higher doses such as 1200 mg/day in critically ill patients, while the variability of inter-individual pharmacokinetics parameters emphasizes the need for therapeutic drug monitoring to ensure optimal exposure.

Identifiants

pubmed: 32307575
doi: 10.1007/s00228-020-02873-5
pii: 10.1007/s00228-020-02873-5
pmc: PMC7306030
doi:

Substances chimiques

Anti-Bacterial Agents 0
Ciprofloxacin 5E8K9I0O4U

Types de publication

Clinical Trial Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

957-967

Références

Intensive Care Med. 2014 Mar;40(3):380-7
pubmed: 24356862
J Antimicrob Chemother. 2010 Aug;65(8):1725-32
pubmed: 20558470
J Intensive Care Med. 2018 Dec;33(12):647-655
pubmed: 29534630
Crit Care. 2013 Jun 15;17(3):R108
pubmed: 23767877
Clin Infect Dis. 2014 Apr;58(8):1072-83
pubmed: 24429437
J Crit Care. 2008 Sep;23(3):422-30
pubmed: 18725050
BMC Infect Dis. 2012 Jul 06;12:152
pubmed: 22768873
J Antimicrob Chemother. 2011 Feb;66(2):227-31
pubmed: 21118912
Antimicrob Agents Chemother. 1993 May;37(5):1073-81
pubmed: 8517694
Antimicrob Agents Chemother. 1993 May;37(5):1065-72
pubmed: 8517693
Antimicrob Agents Chemother. 1998 Mar;42(3):521-7
pubmed: 9517926
Antimicrob Agents Chemother. 1998 Sep;42(9):2235-9
pubmed: 9736541
Clin Pharmacokinet. 2011 Feb;50(2):99-110
pubmed: 21142293
Clin Microbiol Infect. 2016 May;22(5):416-22
pubmed: 26706614
Clin Pharmacol Ther. 2007 Jul;82(1):17-20
pubmed: 17571070
J Antimicrob Chemother. 2019 Jun 1;74(6):1662-1669
pubmed: 30809648
Ann Intensive Care. 2012 Jul 28;2(1):35
pubmed: 22839761
Int J Antimicrob Agents. 2005 Jul;26(1):50-5
pubmed: 15955670
Br J Clin Pharmacol. 2013 Jan;75(1):180-5
pubmed: 22616681
J Intensive Care. 2014 May 07;2(1):31
pubmed: 25520843
J Antimicrob Chemother. 1994 May;33(5):1051-4
pubmed: 8089053
Pharm Res. 1998 Sep;15(9):1463-8
pubmed: 9755901
Antimicrob Agents Chemother. 2004 Jul;48(7):2464-70
pubmed: 15215095
Chemotherapy. 1990;36(2):77-84
pubmed: 2311444
BMC Infect Dis. 2020 Jan 17;20(1):57
pubmed: 31952493
J Antimicrob Chemother. 2018 Mar 1;73(3):564-568
pubmed: 29216348
Intensive Care Med. 2013 Dec;39(12):2070-82
pubmed: 24045886
CPT Pharmacometrics Syst Pharmacol. 2013 Jun 26;2:e50
pubmed: 23836189
Antimicrob Agents Chemother. 1999 Mar;43(3):678-80
pubmed: 10049287
Anaesthesia. 1997 Jun;52(6):531-7
pubmed: 9203878
J Antimicrob Chemother. 1986 Nov;18 Suppl D:83-7
pubmed: 3804907
J Antimicrob Chemother. 2016 Jun;71(6):1643-50
pubmed: 26957490
Arch Intern Med. 1989 Oct;149(10):2269-73
pubmed: 2508586
Am J Kidney Dis. 2005 Aug;46(2):242-52
pubmed: 16112042
Antimicrob Agents Chemother. 1987 May;31(5):709-12
pubmed: 3300537
Clin Pharmacokinet. 2002;41(10):741-50
pubmed: 12162760
AAPS J. 2011 Jun;13(2):143-51
pubmed: 21302010
J Antimicrob Chemother. 2006 Aug;58(2):380-6
pubmed: 16735422
J Antimicrob Chemother. 1994 Mar;33(3):403-17
pubmed: 8040107
J Antimicrob Chemother. 2011 Aug;66(8):1798-809
pubmed: 21653603
Antimicrob Agents Chemother. 2008 Mar;52(3):813-21
pubmed: 18070961
Int J Antimicrob Agents. 2008 Dec;32(6):505-10
pubmed: 18768301
Antimicrob Agents Chemother. 1987 Jun;31(6):860-4
pubmed: 3619418
Interdiscip Perspect Infect Dis. 2012;2012:976273
pubmed: 23097666
JAMA. 1998 Jan 14;279(2):125-9
pubmed: 9440662
J Antimicrob Chemother. 1997 Jul;40(1):121-4
pubmed: 9249215
Comput Methods Programs Biomed. 2008 May;90(2):154-66
pubmed: 18215437
J Clin Pharmacol. 2004 Sep;44(9):1012-22
pubmed: 15317829

Auteurs

Alan Abdulla (A)

Department of Hospital Pharmacy, Erasmus University Medical Center, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands. a.abdulla@erasmusmc.nl.

Omar Rogouti (O)

Department of Hospital Pharmacy, Erasmus University Medical Center, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands.

Nicole G M Hunfeld (NGM)

Department of Hospital Pharmacy, Erasmus University Medical Center, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands.
Department of Intensive Care, Erasmus University Medical Center, Rotterdam, The Netherlands.

Henrik Endeman (H)

Department of Intensive Care, Erasmus University Medical Center, Rotterdam, The Netherlands.

Annemieke Dijkstra (A)

Department of Intensive Care, Maasstad Hospital, Rotterdam, The Netherlands.

Teun van Gelder (T)

Department of Hospital Pharmacy, Erasmus University Medical Center, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands.
Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands.

Anouk E Muller (AE)

Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, The Netherlands.
Department of Medical Microbiology, Haaglanden Medical Center, The Hague, The Netherlands.

Brenda C M de Winter (BCM)

Department of Hospital Pharmacy, Erasmus University Medical Center, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands.

Birgit C P Koch (BCP)

Department of Hospital Pharmacy, Erasmus University Medical Center, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH